Latest News

US FDA accepts Pfizer’s sNDA for Xeljanz to treat ulcerative colitis

US FDA accepts Pfizer’s sNDA for Xeljanz to treat ulcerative colitis

Glenmark secures UK MHRA approval for anti-malarial medication

Glenmark Pharmaceuticals Europe (Glenmark) has secured final approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Maloff Protect, its range of atovaquone /...

Glenmark secures UK MHRA approval for anti-malarial medication

Roivant forms new subsidiary to develop urology therapies

Healthcare firm Roivant Sciences has formed a new subsidiary known as ‘Urovant Sciences’ to develop new therapies for addressing urologic...

Roivant forms new subsidiary to develop urology therapies

Synlogic completes first phase in ongoing R&D collaboration with AbbVie

US-based pharmaceutical firm Synlogic has met the first discovery milestone in its ongoing research and development (R&D) collaboration with...

Synlogic completes first phase in ongoing R&D collaboration with AbbVie

Lundbeck secures rights to IBC's research for Alzheimer's treatment

Lundbeck secures rights to IBC's research for Alzheimer's treatment

Novartis and IBM Watson to optimise cancer care and patient outcomes

Novartis and IBM Watson to optimise cancer care and patient outcomes

Merck and F-star to develop five bispecific immuno-oncology antibodies

German science and technology firm Merck has entered a new strategic collaboration with UK-based biopharmaceutical firm F-star to develop and commercialise five bispecific immuno-oncology...

Merck and F-star to develop five bispecific immuno-oncology antibodies

Innate Pharma acquires anti-C5aR antibody from Novo Nordisk

French biotechnology company Innate Pharma has signed an agreement to acquire a clinical-stage anti-C5a receptor (C5aR) antibody (IPH5401) from Danish pharmaceutical firm Novo Nordisk for...

Innate Pharma acquires anti-C5aR antibody from Novo Nordisk

UK CMA accuses Merck of breaking competition law with discount scheme

UK CMA accuses Merck of breaking competition law with discount scheme

AC Immune and Essex to develop biological treatment for neurodegenerative diseases

AC Immune and Essex to develop biological treatment for neurodegenerative diseases

Cancer Research UK funded scientists to test Zika virus on brain tumours

Scientists funded by Cancer Research UK will investigate the effectiveness of the Zika virus in destroying brain tumour cells, which could lead to new treatments for...

Cancer Research UK funded scientists to test Zika virus on brain tumours

Sobi receives SFDA approval for Orfadin capsules

Sobi receives SFDA approval for Orfadin capsules

Bayer receives FDA priority review for copanlisib to treat follicular lymphoma

Bayer receives FDA priority review for copanlisib to treat follicular lymphoma

X-Chem and Vertex form multi-target genetic disease collaboration

US-based firms X-Chem and Vertex Pharmaceuticals have signed a collaboration agreement to discover new drug leads against targets involved in multiple speciality...

X-Chem and Vertex form multi-target genetic disease collaboration

EU nations urge funding to research new drugs and vaccines for tuberculosis

Leaders representing the French and Netherlands governments have urged for funding to develop new treatment and prevention tools against drug-resistant tuberculosis (TB) at a meeting held in...

EU nations urge funding to research new drugs and vaccines for tuberculosis

Eli Lilly Scores Phase III Migraine Success with Galcanezumab

Eli Lilly Scores Phase III Migraine Success with Galcanezumab

US FDA issues CRL to Hikma’s generic version of GSK’s Advair Diskus

Hikma Pharmaceuticals has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the abbreviated new drug application (ANDA) of its generic version...

US FDA issues CRL to Hikma’s generic version of GSK’s Advair Diskus

Exscientia signs collaboration deal with Sanofi for multiple product development

Artificial Intelligence-driven drug discovery firm Exscientia has formed a strategic research collaboration with Sanofi by signing a licence option agreement in the high-interest area of...

Exscientia signs collaboration deal with Sanofi for multiple product development

Immunocore and GSK identify second new ImmTAC for cancer treatment

UK-based biotechnology firm Immunocore and GlaxoSmithKline (GSK) have identified a lead compound as part of their second discovery...

Immunocore and GSK identify second new ImmTAC for cancer treatment

New collaborative project launched to engage universities in drug discovery for neglected diseases

A new collaborative project has been launched to engage students from five universities in the US, the UK and India to help discover new drugs for neglected...

New collaborative project launched to engage universities in drug discovery for neglected diseases

Dementia Discovery Fund to invest $5m in Cerevance to advance Alzheimer’s treatment

SV Life Sciences-managed Dementia Discovery Fund (DDF), which develops disease modifying drugs for dementia, has announced a $5m investment in the initial financing round of start-up drug...

Dementia Discovery Fund to invest $5m in Cerevance to advance Alzheimer’s treatment
cachename:Newscachekey:rd-137342983_-779801984_rd-1665407042_1857678299_rd-488908060_1460672566_ap1460672566_1857678299_541212976